Openbookopenbook
Equity
Revvity(0KHE)
USD --+0.00%
Reward50Moderate
Risk46Moderate
📊75%Data
0KHE
+0.0 · +0.00%
USD · LSE
Revvity |
Balanced
Market Cap:—
ℹ️
Reward Rating
50
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
46
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0KHE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Revvity?

provides health sciences solutions, technologies, and services.

0KHE · Verdict

Moderate reward · moderate risk

0KHE leads on cash flow with the rest of the factors in line with peers.

Based on 88% data coverage

0KHE · Verdict

What’s working & what to watch

Strengths 1

  • Cash flow72/100

    18% free-cash-flow margin

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Revvity?

provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. The company is listed on the LSE in UK, and a P/E ratio of 0.1x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (50)

The scoring profile indicates limited reward potential at this time, with momentum and profitability offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market CapN/A
P/E Ratio0.1322
Dividend Yield0.33%
52 Week High117.9012
52 Week Low81.2659
Last AnnualJanuary
IPO DateN/A
IncorporatedUK
Shares Outstanding111M
No. of Employees11,000
IndustryN/A
ExchangeLSE
Beta1.129
CurrencyUSD
Websitewww.revvity.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.